Library / Peptides / Immune Support / Vilon
No human data · Grade D

Vilon

Vilon (Lys-Glu Dipeptide Bioregulator)
Score
48 / 100
Structure
Dipeptide (Lys-Glu)
Origin
Khavinson (Russia)
Status
Preclinical / Russian claims
TL;DR
01
A synthetic dipeptide (Lys-Glu) from Vladimir Khavinson's 'bioregulator' program, promoted as an immune-modulating and anti-aging peptide.
02
The Khavinson group reports that such short peptides can enter cells, bind DNA in a sequence-specific way, and extend lifespan by 20–40% in rodents.
03
But those results are from the originating Russian group, and there are no independent human trials — vilon is rated No Human Data.
04
As a two-amino-acid peptide, its specificity and real-world activity are also biologically contentious.
05
It is not approved and is sold as a research chemical.
Independent human trials
None
no interventional RCTs
Rodent lifespan (group claims)
+20–40%
originating group
Mechanism (in vitro)
DNA-sequence binding
short-peptide penetration
Evidence source
Khavinson group
not independently replicated
Approval
None
research chemical
Part 01 · How it works

Mechanism.

Vilon is one of the shortest of the Khavinson 'bioregulator' peptides — just two amino acids. The theory behind the whole family is that these tiny peptides slip into cells and even the nucleus, where they bind DNA at specific sequences and switch genes on or off, and the group reports that long-term dosing extends rodent lifespan. It's an ambitious idea. The problem is that essentially all of the supporting evidence comes from the one Russian group that developed them, with no independent human trials, and the claim that a two-amino-acid peptide has that kind of specific gene-regulating power is scientifically contentious.

A two-letter 'message' that its inventors say reprograms genes and extends rodent lifespan — a bold claim resting almost entirely on one lab's work, untested independently in humans.

Bioregulator dipeptide
Lys-Glu; part of the Khavinson short-peptide bioregulator program.
Proposed gene regulation
Short peptides reported to penetrate the nucleus and bind DNA sequence-specifically (in vitro).
Rodent lifespan claims
The group reports 20–40% mean-lifespan extension and reduced tumorigenesis in rodents.
Evidence stage
In vitro + rodent + Russian clinical claims; no independent human trials.
Part 02 · Dosing & administration

How it's taken.

Community-reported · unregulated

Values below reflect commonly reported community protocols for Vilon. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
Injectable KE dipeptide ~1 mg/day SC; oral/sublingual bioregulator capsules are dosed higher (~10–20 mg) but uncharacterized
Subcutaneous (parenteral) primarily; an oral/sublingual capsule form is also marketed · Once daily
Duration
5-day pulse per ~4-week cycle, repeated seasonally
·
The parenteral Vilon (Lys-Glu / KE dipeptide) is given in the microgram-to-~1 mg range — much lower than the ~10–20 mg oral-capsule figure, which appears to be a different product form.
·
None of these figures come from a controlled human trial; they are Russian-protocol/community conventions and are not internationally standardized.
·
Outside Russia, Vilon is an unregulated research chemical with no purity or dose guarantee.
Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Common
Human tolerability
No independent human safety data.
Uncharacterized (independent)
Serious · rare
Long-term independent safety
No independent long-term human data.
Unknown
Product-quality risk
Research-chemical supply; purity/dose unknown.
Source-dependent
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to vilon (Lys-Glu) or any component
×
Organ transplant recipients on immunosuppression
×
Active autoimmune disease in flare
Relative · discuss first
!
Pregnancy or breastfeeding — no data
!
Anyone expecting independently validated benefit — none exists
!
Reliance on it for immune disease in place of evidence-based care
Interactions
Immunosuppressants
Vilon is a thymic bioregulator that may stimulate immune function; could oppose immunosuppressive therapy
Moderate
Immune checkpoint inhibitors
Theoretical additive immune activation
Minor
Corticosteroids
High-dose corticosteroids may reduce vilon's immunostimulatory efficacy
Minor
Labs to monitor
CBC with Differential
Baseline and at end of cycle
Monitor immune parameters (thymic bioregulator)
T-Cell Subsets (CD4, CD8)
Baseline and at end of cycle
Vilon targets thymic/immune function
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
General metabolic safety
Part 04 · Evidence

How strong is the evidence?

48
Grade D
Grade D, No Human Data. Vilon rests on an ambitious gene-regulation/longevity thesis supported almost entirely by its originating Russian group, with no independent human trials and biological plausibility questions for such a short peptide.
Mechanistic plausibility
Short-peptide sequence-specific gene regulation is contentious; in-vitro DNA binding shown by the originating group.
50
Human evidence
No independent human trials.
20
Safety & tolerability
Reported benign, but no independent human safety data.
55
Durability
No independent human outcome data.
45
Independence
Evidence concentrated in the originating group; not independently replicated.
30
Part 05 · Research log

Every study we cite.

We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.

01
2009
Biogerontology Flagged
Peptide bioregulation of aging: results and prospects (review)
Summarizes claims that Khavinson short peptides (di-, tri-, tetrapeptides) extend rodent mean lifespan by 20–40% and suppress tumorigenesis, with reported multi-year clinical applications.
Narrative review by the originating group · Authored by the originating group; not independent confirmation.
PMID 19830585 ↗
Low (review, single-group)
Evidence against

What didn't work, and where the evidence is thin.

Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.

01
Bold longevity claims, single-group evidence, no independent human trials
Mechanism limit
Biogerontology · 2009
Vilon's benefits (immune modulation, longevity) are reported almost exclusively by the group that created it, and there are no independent human randomized trials. The gene-regulation mechanism proposed for such a short peptide is scientifically contentious.
What this means: Extraordinary claims (lifespan extension) resting on one lab's non-independent evidence warrant strong skepticism, not adoption.
PMID 19830585 ↗
Part 06 · Cost & access

Where it's available, at what price.

Russia
Marketed (bioregulator)
Sold within the Khavinson bioregulator framework.
Russian market
United States
Not approved
No approved product; research chemical.
Grey-market; unregulated
European Union
Not approved
No approved product.
N/A
United Kingdom
Not approved
No approved product.
N/A
The Peptide Column takes no affiliate commission from any source. Vilon has no independent human trials and is not approved anywhere; consumer supply is research-grade and unregulated, and its longevity claims are not independently confirmed. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment

Questions to bring.

01
Are there any peer-reviewed human clinical trials of Vilon outside of Russian research groups?
02
What purity and safety standards apply to Vilon sources available to consumers?
03
Given the lack of independent evidence, what are the risks of this compound versus established immune modulators?
04
Could a simple dipeptide survive oral administration or does it require injection?
References

Every citation, numbered.

Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.

  1. 01.
    Peptide bioregulation of aging: results and prospects (review) · Biogerontology, 2009 · PMID 19830585 ↗
  2. 02.
    St. Petersburg Institute of Bioregulation and Gerontology. Khavinson bioregulator program